



HHS Public Access

Author manuscript

CNS Spectr. Author manuscript; available in PMC 2018 April 06.

Published in final edited form as:

CNS Spectr. 2015 February ; 20(1): 39–47. doi:10.1017/S1092852915000024.

Antidepressant Medication Use, Depression and the Risk of Preeclampsia

Lyndsay Ammon Avalos, PhD, MPH [Research Scientist/Epidemiologist],

Kaiser Permanente Northern California, Division of Research, 2000 Broadway, Oakland, CA 94612

Hong Y. Chen, MPH [Programmer/Analyst], and

Programmer/Analyst, Kaiser Permanente Northern California, Division of Research, 2000 Broadway, Oakland, CA 94612

De-Kun Li, MD, PhD [Research Scientist/Epidemiologist]

Kaiser Permanente Northern California, Division of Research, 2000 Broadway, Oakland, CA 94612

Abstract

Objective—To assess the effects of depression and antidepressant medication use during pregnancy on the risk of preeclampsia.

Methods—We conducted a retrospective, population-based cohort study linking automated clinical and pharmacy databases including comprehensive electronic medical records of 21,589 pregnant Kaiser Permanente Northern California members between 2010 and 2012.

Results—The overall risk of preeclampsia was 4.5%. The timing of antidepressant medication exposure was an important factor. A significant increase in the risk of preeclampsia emerged for women with a depression diagnosis who took antidepressant medications during the second trimester compared to women with untreated depression (adjusted Relative Risk (aRR): 1.6, 95% CI: 1.06, 2.39), and to women without depression (aRR: 1.70, 95% CI: 1.30, 2.23). Similar associations existed for women who took antidepressant medications, but without depression. In contrast, depressed women with psychotherapy showed no increased risk of preeclampsia compared to women with untreated depression or no depression. There was also a statistically significant relationship between the duration of antidepressant medication use and preeclampsia. The observed association appeared stronger for SSRI use, although a non-significant trend was also noted for use of NDRIs and SNRIs.

Conclusion—Study findings suggest that the antidepressant use during pregnancy may increase the risk of preeclampsia, especially the use during the second trimester.

Objective

Antidepressant medications are used by up to 13% of pregnant women^{1,2}, with the trend suggesting a steady increase in their use during pregnancy¹. To date most of the research evaluating antidepressant use during pregnancy has concentrated on outcomes of the fetus, but recent research has begun to focus on the impact they may have on maternal health. Preeclampsia is one specific outcome that has garnered attention given the increased risk noted among women with depression³⁻⁸. Preeclampsia is the most severe form of hypertensive disorders during pregnancy affecting 2% - 5% of pregnant women⁹⁻¹³ and it can have serious consequences on maternal and fetal health.

Toh et al⁵ were one of the first investigators to explore the association of antidepressants with preeclampsia and documented a nearly 400% increase in the risk of preeclampsia for women continuing selective serotonin reuptake inhibitors (SSRIs) after their first trimester. Since this study, three others have reported an elevated risk of preeclampsia associated with antidepressant medications, although of a much smaller magnitude of risk (adjusted relative risks ranging between 1.2 – 3.4)⁶⁻⁸. Two of these four investigations reported a significant increase in the risk of preeclampsia with SNRIs and TCAs but not with SSRIs.^{6,7}

However, some of the studies were limited in their generalizability (e.g. a lack of diversity^{6,8} and a special population (Medicaid recipients)⁷). One study relied on self-reported depression and antidepressant medication use, which are subject to recall error or bias⁵. Most did not take into account potential confounding factors such as pre-pregnancy body mass index (BMI)⁷, smoking^{6,7}, diabetes⁸, chronic hypertension⁸, other mental health conditions^{5,8} or other indications for antidepressant medication use^{5,8}. The sample sizes of one study limited the ability to assess exposure to non-SSRI antidepressant medications⁵. Finally, others failed to control for confounding by depression severity^{5,8}.

To further examine the effect of depression and antidepressant use on the risk of preeclampsia, we conducted a large, population-based, retrospective cohort study based on information from a racially/ethnically diverse population of 21,589 pregnant Kaiser Permanente Northern California members between 2010 and 2012. We build on previous research by including two additional cohorts of women to address the issue of confounding: 1) women without depression but taking antidepressant medications for another indication, 2) women with depression and receiving psychotherapy. The inclusion of this second cohort attempts to address the issue of confounding by severity (i.e., depression severity) with the assumption that women who chose psychotherapy have a similar disease severity to those treated with antidepressants.

Methods

Data Sources

This study was conducted among the Kaiser Permanente Northern California (KPNC) member population of pregnant women. In 2009, KPNC implemented a universal peripartum depression screening program. Pregnant women entering prenatal care are screened for depression at their first prenatal visit using the Patient Health Questionnaire

(PHQ-9). These data along with diagnoses of depression and preeclampsia, health services utilization such as psychotherapy, dispenses of prescription drugs and birth delivery data are available through KPNC's well-established automated clinical and pharmacy databases. This study was approved by the Kaiser Permanente Northern California Institutional Review Board.

Study Population

We conducted a population-based, retrospective cohort study of pregnant KPNC women aged 18 or older who gave birth between January 1, 2010 and December 31, 2012. Women who were screened for depression in early pregnancy, had a depression diagnosis or were taking antidepressant medications during pregnancy were included. We excluded women with multi-fetal gestations. Women with a history of hypertension were also excluded as they were considered to have chronic hypertension. To avoid non-independent observations, only the first pregnancy was included for women with more than one pregnancy during the time period.

Exposure

Depression: Depression during pregnancy was defined as either 1) a clinical depression diagnosis between 6 months prior to the woman's last menstrual period (LMP) and 20 completed weeks of gestation or 2) a PHQ-9 score ≥ 10 in the first 20 weeks of pregnancy. The PHQ-9 has been validated as an instrument for screening for depression in obstetric patients with high sensitivity ($> 88\%$) and specificity ($> 88\%$) for scores ≥ 10 ¹⁴⁻¹⁸. It has been adopted by clinicians and researchers for screening in populations including pregnant and postpartum women¹⁹⁻²⁴ and is considered the dimensional depression measure in the DSM-V classification manual²⁵.

The first date of the LMP was determined based on gestational age recorded in the KPNC clinical databases in combination with the calendar date at delivery (last menstrual period = date at delivery – gestational age at delivery). To avoid potential reverse causation, we set the exposure window to end immediately before preeclampsia can be diagnosed (20 weeks gestation). Depression diagnoses were defined as *International Classification of Diseases, Ninth Revision (ICD-9)*, codes 296.20-296.25, 296.30 – 296.35, 298.0, 300.4, 309, 311, 648.4x.

Antidepressant medication exposure: Women exposed to antidepressant medications during pregnancy were identified through linkage to information on dates of drug dispensation and days of supply from the pharmacy database. Please see Appendix 1 for a list of antidepressant medications identified. Antidepressant use during pregnancy was defined as having at least one pharmacy dispensing record for the time period between the first day of the woman's last menstrual period (LMP) and 20 completed weeks of gestation.

The timing of antidepressant medication exposure was categorized as 1) first trimester only exposure or 2) any second trimester exposure. First trimester only exposure included exposure to antidepressant medications in the first trimester (LMP through 12 weeks gestation), but not during the second trimester (13 – 20 weeks gestation). Any second

trimester exposure was defined as antidepressant medication exposure between 12 weeks and 20 weeks gestation.

Duration of antidepressant use was categorized into three categories (1-60, 61-120, 121-140) and started from either the first day of their LMP (if they started prior to pregnancy) or the actual start date (if after the LMP) and ending at 20 completed weeks of gestation or the actual end date (if before 20 weeks of gestation). The total duration of exposure could not exceed 140 days (20 weeks of gestation).

The class of antidepressant medication was categorized in two ways for each class of medication; 1) any use or 2) use of only that class. Six classes of antidepressants were assessed: tricyclic antidepressant (TCA), selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), norepinephrine-dopamine reuptake inhibitor (NDRI), serotonin antagonist and reuptake inhibitor (SARI), and any other classes of antidepressant medications (Other class).

Psychotherapy: Psychotherapy visits between LMP and 20 weeks gestation were ascertained from utilization databases.

Exposure Cohorts

Five cohorts were established based on a combination of depression, antidepressant medication use and psychotherapy. The first two cohorts included women exposed to antidepressant medications during pregnancy: 1) antidepressant use with a depression diagnosis or positive PHQ-9 score, and 2) antidepressant use without depression or positive PHQ-9 score. Two additional cohorts included women with depression not treated pharmacologically: 1) depression and psychotherapy and, 2) untreated depression. The final cohort consisted of women without depression, or having used any antidepressant medications or received psychotherapy (between LMP and delivery).

Outcome

Preeclampsia: Preeclampsia was defined as any of the following ICD-9 codes occurring after 20 weeks gestation: 642.4, 642.5, 642.6, or 642.7.

Covariates—The following potential confounders were considered: *maternal age, race/ethnicity, marital status, parity, alcohol use and smoking (between LMP and 20 weeks gestation), pre-pregnancy body mass index (BMI) (underweight, normal, overweight/obese), pre-existing or gestational diabetes*, a dichotomous variable for *other indications for antidepressant medication use* for six months prior to LMP through 20 weeks gestation (anxiety, migraines, sleep disorders, chronic musculoskeletal pain, peripheral neuropathic pain, fibromyalgia, rheumatoid arthritis, inflammatory bowel disease, or gastrointestinal ulcers)²⁶, and a dichotomous variable for *other mental health disorders* (6 months prior to LMP to 20 weeks gestation).

Data Analysis

Characteristics of the five exposure cohorts were compared using chi-square tests. Logistic regression models were conducted comparing the five exposure cohorts to assess the risk of preeclampsia associated with antidepressant medication use and depression during pregnancy. Additional logistic regression models were conducted to assess the impact of timing of antidepressant medication exposure, duration of use and class of antidepressant.

Logistic regression produces an adjusted odds ratio that approximates the relative risk when the disease outcome is rare. Given that the prevalence of preeclampsia is less than 10%, we report the odds ratios as relative risks in this study.

Results

Overall the study included 21,589 women. Of these women, 1,732 (8%) had depression and were treated with antidepressant medications; 149 (<1%) did not have depression but took antidepressant medications during pregnancy; 1,961 (9%) had depression and received psychotherapy; 1,345 (6%) had untreated depression, and 16,402 (76%) did not have depression and did not take any antidepressant medications or psychotherapy for depression. Women taking antidepressant medications who had depression were more likely to be identified by a DSM-IV diagnosis (n=1696, 98%) compared to women with depression who received psychotherapy (n=49, 49%) and untreated depression (n=198, 15%). Of the 149 women taking antidepressants without depression, 32 (21%) had an anxiety diagnosis, 71 (48%) had another non-mental health indication and 46 (31%) did not have any indication listed. Comparisons of the characteristics of the five cohorts are in Table 1.

The overall risk of preeclampsia in our study was 4.5%, and ranged from 2.7% for women taking antidepressant medications without depression, to 6.9% for women taking antidepressant medications who did have depression.

Exposure to antidepressant medication during pregnancy and the risk of preeclampsia

After adjusting for all covariates, compared to women without depression, women who took antidepressant medications and had depression had nearly a 40% increase in the risk of preeclampsia (95% CI: 1.06, 1.76) (Table 2), while women who took antidepressant medications and did not have depression had a non-significant decreased risk of preeclampsia (aRR: 0.5, 95% CI: 0.19, 1.44). When the timing of antidepressant medication exposure was considered, the results for the two antidepressant cohorts mirrored each other. Among antidepressant users with depression, antidepressant medication exposure in the second trimester was significantly associated with a 70% increase in the risk of preeclampsia compared to women without depression. There were no significant differences in the risk of preeclampsia associated with first trimester only exposure when compared to women without depression. Among the antidepressant users without depression, a nonsignificant increased risk of preeclampsia emerged for second trimester exposure when compared to women without depression (aRR: 1.34, 95% CI: 0.5, 3.8). None of the women in this cohort who were exposed to antidepressant medications during the first trimester only had preeclampsia.

Similar patterns to those described above emerged when the women in the two antidepressant medication cohorts were compared to women with depression who received psychotherapy and women with untreated depression.

Depression with psychotherapy and the risk of preeclampsia

There was no increased risk of preeclampsia for women with depression receiving psychotherapy compared to women without depression (aRR: 0.8; 95% CI: 0.6, 1.04) or women with untreated depression (aRR: 0.8, 95% CI: 0.6, 1.2).

Untreated depression and the risk of preeclampsia

The risk of preeclampsia for women with untreated depression did not differ from women without depression (aRR: 0.95, 95% CI: 0.7, 1.3) (Table 2).

Sensitivity Analyses

We assessed the sensitivity of our results to our definition of depression by replicating all analyses in Table 2 and excluding all women identified with depression using the PHQ-9. Similar trends appeared for all relationships (results not shown). Additionally, we assessed the prevalence of preeclampsia by indication for antidepressant medication use in the cohort without depression: 3% (n=1) for women with an anxiety diagnosis, 1% (n=1) for women with another indication, and 4% (n=2) for women without an indication.

Duration of exposure to antidepressant medications

We found a significant relationship with duration of use (Test for trend p=0.01); increased duration of use appeared to be associated with a greater risk of preeclampsia

Class of Antidepressant Medication

SSRIs (n= 1,499, 80% of the women who took antidepressant medications) were the most prevalent antidepressant medication used in our population (Table 4). NDRIs were the second most prevalent (n=236, 13%) followed by TCAs (n=154, 8%). When compared to women without depression, the adjusted relative risk of preeclampsia for exposure to SSRI medications was 1.3 (95% CI: 1.0, 1.8 for exposure to only SSRIs), suggesting a borderline increased risk. We found a 40% increase in the risk of preeclampsia related to any exposure to SSRI medications (95% CI: 1.06 -1.85). There also may be an increased risk of preeclampsia associated with use of other antidepressants but the statistical significance of our findings was limited by small sample sizes and the low frequency of our primary outcome (i.e., preeclampsia).

Discussion

Our findings suggest that antidepressant medication use during the second trimester (prior to 20 weeks) may increase the risk of preeclampsia. Timing of exposure emerged as an important factor in the relationship between antidepressant medication use and preeclampsia. We acknowledge that the results were not statistically significant for women without depression exposed to antidepressants during the second trimester. These findings were based on small numbers, but highlight the similar trend that appeared.

The class of antidepressant medication use may also be important. In our investigation, SSRIs were the only class of antidepressant medication in which a statistically significant relationship emerged but other classes, specifically SNRIs and NDRI, should be further examined for a possible increased risk of preeclampsia as well.

The relationship between duration of antidepressant exposure and preeclampsia that we report here supports findings from other studies which have found a greater risk of preeclampsia among women who took antidepressant medications for a longer duration⁵⁻⁷. In addition, other studies have also documented timing of antidepressant exposure may be an important factor, with second trimester exposure resulting in the highest risk of preeclampsia^{5,6}.

From a biological perspective, it is plausible that there would be a relationship between antidepressant medications and preeclampsia. SSRIs, SNRIs, and TCAs are the three main classes of antidepressants prescribed to treat depression. They are also known as monoamine neurotransmitter reuptake inhibitors as they are designed to target the pathways of the three main neurotransmitters involved in depression (serotonin, norepinephrine, and dopamine). Monoamine neurotransmitter reuptake inhibitors constrain the reuptake of serotonin, norepinephrine, and dopamine and thus may change the extracellular concentrations of these three neurotransmitters. One potential mechanism through which antidepressants may impact the risk of preeclampsia may be through the type and amount of monoamine neurotransmitter reuptake inhibition^{5,6,27}. Research from both human *in vitro* models and animal models suggest extracellular levels of serotonin and norepinephrine in the placenta may be involved in inducing vasoconstriction²⁸⁻³¹. In *in vitro* human models, serotonin has been documented to increase placental chorionic vein and umbilical artery vasoconstriction^{28,29}. Rat models have identified norepinephrine as a vasoconstrictor in uterine vascular beds³⁰. In addition, a decrease in uterine artery blood flow and fetal oxygenation has been found in pregnant sheep infused with fluoxetine, an SSRI³¹. SSRIs have also been noted to inhibit synthesis of nitric oxide, a vasodilator that may play a role in vascular tone and reactivity³²⁻³⁴. Likely due to their noradrenergic effects, SNRIs can cause elevated diastolic blood pressure³⁵. Further supporting a biological mechanism for the relationship between antidepressant medication exposure and preeclampsia, increased serum levels of both serotonin and norepinephrine have been found in women with preeclampsia³⁶⁻³⁸.

We attempted to control for confounding by depression severity or indication. First, we included a comparison group of women with depression in psychotherapy as a cohort of women who may have a similar level of depression severity to those taking antidepressant medications. Psychotherapy is a safe alternative to antidepressant medications that pregnant women may be more likely to utilize given the potential adverse fetal and neonatal outcomes associated with antidepressant medications³⁹⁻⁴¹. In our study, women with depression receiving psychotherapy did not have an increased risk of preeclampsia compared to either women with untreated depression or women without depression. Yet, women exposed to antidepressant medications in the second trimester had an increased risk of preeclampsia when compared to women with depression receiving psychotherapy though no difference was found with 1st trimester antidepressant exposure. It could be argued that women who receive antidepressant medications during pregnancy may have more severe illness than

women receiving psychotherapy. This is a possibility that we cannot assess in this study. An additional limitation found with this particular comparison may be the relatively liberal definition of receiving psychotherapy, namely, that subjects needed only one visit (or more) to qualify.

We attempted to address the issue of confounding by indication by including a cohort of women without depression who were taking antidepressant medications for various indications. There are several indications listed by the FDA²⁶ for which antidepressant medications may be prescribed. We discovered that there was no increased risk found with this cohort in comparison to women who did not have depression or exposure to antidepressants, suggesting that the possibility that depression itself was increasing preeclampsia risk could not be ruled out.

Misclassification of depression is a possibility as our definition included women with a positive PHQ-9 screen or a depression diagnosis. However, our results were replicated when we included women identified with depression only by DSM-IV diagnoses.

Misclassification of exposure to antidepressant medication is also possible. We ascertained data on antidepressant prescriptions and dispensing, however we are limited in our ability to assess actual use. Any misclassification of antidepressant medication use would likely be non-differential and would bias the results toward the null.

Women who remain on antidepressant medications during pregnancy may have other risk factors that would increase their risk for preeclampsia. Attempts were made to address many of these potential factors in both our study design and analyses. First, we restricted the sample to women without pre-existing hypertension or multi-fetal gestations. Second, we controlled for several factors known to be associated with both antidepressant use and preeclampsia such as pre-pregnancy body mass index (BMI), diabetes, race/ethnicity and smoking. Our findings persisted despite these restrictions and adjustments. For any other potential unmeasured confounder to influence our results, it would have to be prevalent in our study population and strongly associated with both antidepressant medication exposure and preeclampsia⁴².

We did not control for multiple comparisons. However, given that the findings that emerged for the various comparisons related to depression, antidepressant exposure and preeclampsia were all in the same direction and of similar magnitude, these results are not likely due to chance.

Conclusion

In conclusion, an increased risk of preeclampsia was associated with antidepressant use during the second trimester (prior to 20 weeks) of gestation in comparison to women who were not depressed or receiving medication. We did not find an increased risk for preeclampsia among women who received antidepressants without a depression diagnosis, or those who received psychotherapy for their depression. The results of this study suggest that clinicians may wish to consider increased monitoring for preeclampsia of women taking antidepressant medications in the second trimester.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This project was funded by a grant awarded to Lyndsay A. Avalos by Kaiser Permanente Community Benefits. Lyndsay A. Avalos's time was also partially funded by UCSF-Kaiser/DOR Building Interdisciplinary Research Careers in Women's Health Program (K12HD052163, NICHD/NIH, Guglielmo, PI).

References

1. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. *American journal of obstetrics and gynecology*. Jun; 2007 196(6):544 e541–545. [PubMed: 17547888]
2. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. *American journal of obstetrics and gynecology*. Feb; 2008 198(2):194 e191–195. [PubMed: 17905176]
3. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O. Depression and anxiety in early pregnancy and risk for preeclampsia. *Obstet Gynecol*. Apr; 2000 95(4):487–490. [PubMed: 10725477]
4. Qiu C, Sanchez SE, Lam N, Garcia P, Williams MA. Associations of depression and depressive symptoms with preeclampsia: results from a Peruvian case-control study. *BMC Womens Health*. 2007; 7:15. [PubMed: 17900360]
5. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernandez-Diaz S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. *Am J Psychiatry*. Mar; 2009 166(3):320–328. [PubMed: 19122006]
6. Palmsten K, Setoguchi S, Margulis AV, Patrick AR, Hernandez-Diaz S. Elevated Risk of Preeclampsia in Pregnant Women With Depression: Depression or Antidepressants? *Am J Epidemiol*. Apr 10.2012
7. Palmsten K, Huybrechts KF, Michels KB, et al. Antidepressant use and risk for preeclampsia. *Epidemiology*. Sep; 2013 24(5):682–691. [PubMed: 23873072]
8. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. *Psychol Med*. Oct; 2010 40(10):1723–1733. [PubMed: 20047705]
9. Hernandez-Diaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. *BMJ*. 2009; 338:b2255. [PubMed: 19541696]
10. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. *Am J Hypertens*. May; 2008 21(5):521–526. [PubMed: 18437143]
11. Dahlstrom BL, Engh ME, Bukholm G, Oian P. Changes in the prevalence of pre-eclampsia in Akershus County and the rest of Norway during the past 35 years. *Acta Obstet Gynecol Scand*. 2006; 85(8):916–921. [PubMed: 16862468]
12. Xiong X, Demianczuk NN, Saunders LD, Wang FL, Fraser WD. Impact of preeclampsia and gestational hypertension on birth weight by gestational age. *Am J Epidemiol*. Feb 1; 2002 155(3):203–209. [PubMed: 11821244]
13. Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. *Am J Obstet Gynecol*. Aug; 1990 163(2):460–465. [PubMed: 2386132]
14. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. Sep; 2001 16(9):606–613. [PubMed: 11556941]
15. Spitzer RL, Williams JB, Kroenke K, Hornyak R, McMurray J. Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetric-gynecologic patients: the PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. *Am J Obstet Gynecol*. Sep; 2000 183(3):759–769. [PubMed: 10992206]

16. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. *Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.* *Jama.* Nov 10; 1999 282(18):1737–1744. [PubMed: 10568646]
17. Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. *J Gen Intern Med.* Nov; 2007 22(11):1596–1602. [PubMed: 17874169]
18. Wittkamp KA, Naeije L, Schene AH, Huyser J, van Weert HC. Diagnostic accuracy of the mood module of the Patient Health Questionnaire: a systematic review. *Gen Hosp Psychiatry Sep-.* Oct; 2007 29(5):388–395.
19. Desai MM, Rosenheck RA, Craig TJ. Case-finding for depression among medical outpatients in the Veterans Health Administration. *Medical care.* Feb; 2006 44(2):175–181. [PubMed: 16434917]
20. Engel CC, Oxman T, Yamamoto C, et al. RESPECT-Mil: feasibility of a systems-level collaborative care approach to depression and post-traumatic stress disorder in military primary care. *Mil Med.* Oct; 2008 173(10):935–940. [PubMed: 19160608]
21. Arnow BA, Hunkeler EM, Blasey CM, et al. Comorbid depression, chronic pain, and disability in primary care. *Psychosomatic medicine.* Mar-Apr; 2006 68(2):262–268. [PubMed: 16554392]
22. Katzelnick DJ, Von Korff M, Chung H, Provost LP, Wagner EH. Applying depression-specific change concepts in a collaborative breakthrough series. *Jt Comm J Qual Patient Saf.* Jul; 2005 31(7):386–397. [PubMed: 16130982]
23. Bremer RW, Scholle SH, Keyser D, Houtsinger JV, Pincus HA. Pay for performance in behavioral health. *Psychiatric services.* Dec; 2008 59(12):1419–1429. [PubMed: 19033169]
24. Sederer LI, Silver L, McVeigh KH, Levy J. Integrating care for medical and mental illnesses. *Prev Chronic Dis.* Apr. 2006 3(2):A33. [PubMed: 16539774]
25. Andrews G, Anderson TM, Slade T, Sunderland M. Classification of anxiety and depressive disorders: problems and solutions. *Depression and anxiety.* 2008; 25(4):274–281. [PubMed: 18415950]
26. Center for Medicare and Medicaid Services. Antidepressant Medications: US Food and Drug Administration-Approved Indications and Dosages for Use in Adults. Center for Medicare and Medicaid Services; Aug 2013. 2013 Medicaid Integrity Program.
27. Bolte AC, van Geijn HP, Dekker GA. Pathophysiology of preeclampsia and the role of serotonin. *Eur J Obstet Gynecol Reprod Biol.* Mar; 2001 95(1):12–21. [PubMed: 11267715]
28. Bjoro K, Stray-Pedersen S. In vitro perfusion studies on human umbilical arteries. I. Vasoactive effects of serotonin, PGF2 alpha and PGE2. *Acta Obstet Gynecol Scand.* 1986; 65(4):351–355. [PubMed: 3461666]
29. Gonzalez C, Cruz MA, Sepulveda WH, Rudolph MI. Effects of serotonin on vascular tone of isolated human placental chorionic veins. *Gynecol Obstet Invest.* 1990; 29(2):88–91. [PubMed: 2335314]
30. Yousif MH, Chandrasekhar B, Kadavil EA, Oriowo MA. Noradrenaline-induced vasoconstriction in the uterine vascular bed of pregnant rats chronically treated with L-NAME: role of prostanoids. *J Cardiovasc Pharmacol.* Sep; 2003 42(3):428–435. [PubMed: 12960689]
31. Morrison JL, Chien C, Riggs KW, Gruber N, Rurak D. Effect of maternal fluoxetine administration on uterine blood flow, fetal blood gas status, and growth. *Pediatr Res.* Apr; 2002 51(4):433–442. [PubMed: 11919327]
32. Abman SH. New developments in the pathogenesis and treatment of neonatal pulmonary hypertension. *Pediatr Pulmonol Suppl.* 1999; 18:201–204. [PubMed: 10093143]
33. Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. *Arthritis Rheum.* Dec; 1999 42(12):2561–2568. [PubMed: 10616001]
34. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. *Psychopharmacol Bull.* 1996; 32(4):653–658. [PubMed: 8993087]
35. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. *The Journal of clinical psychiatry.* Oct; 1998 59(10):502–508. [PubMed: 9818630]

36. Manyonda IT, Slater DM, Fenske C, Hole D, Choy MY, Wilson C. A role for noradrenaline in pre-eclampsia: towards a unifying hypothesis for the pathophysiology. *Br J Obstet Gynaecol.* Jun; 1998 105(6):641–648. [PubMed: 9647155]
37. Kaaja RJ, Moore MP, Yandle TG, Ylikorkala O, Frampton CM, Nicholls MG. Blood pressure and vasoactive hormones in mild preeclampsia and normal pregnancy. *Hypertens Pregnancy.* 1999; 18(2):173–187. [PubMed: 10476619]
38. Middelkoop CM, Dekker GA, Kraayenbrink AA, Popp-Snijders C. Platelet-poor plasma serotonin in normal and preeclamptic pregnancy. *Clin Chem.* Aug; 1993 39(8):1675–1678. [PubMed: 8353954]
39. Wisner KL, Sit DK, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. *The American journal of psychiatry.* May; 2009 166(5):557–566. [PubMed: 19289451]
40. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. *The New England journal of medicine.* Oct 3; 1996 335(14):1010–1015. [PubMed: 8793924]
41. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. *Arch Gen Psychiatry.* Aug; 2006 63(8):898–906. [PubMed: 16894066]
42. Savitz, DA. *Interpreting Epidemiologic Evidence.* New York: Oxford University Press Inc; 2003.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1
Demographic Characteristics, Behavioral Factors, Health, and Mental Health Diagnoses by Exposure Cohort for 21,598 pregnant women in Kaiser Permanente Northern California between 2010-2012

	No depression n (%)	Untreated depression n (%)	Depression and psychotherapy n (%)	Antidepressant use and depression n (%)	Antidepressant use and no depression n (%)	p-value
Total N	16402	1345	1961	1732	149	
<i>Age</i>						
18-20	479 (3)	67 (5)	208 (10.6)	80 (5)	3 (2)	<0.0001
21-25	2256 (14)	207 (15)	383 (19.5)	239 (13.8)	20 (13)	
26-30	5543 (34)	429 (32)	533 (27)	495 (28.6)	50 (34)	
31-35	5413 (33)	422 (31)	540 (28)	570 (32.9)	44 (30)	
36-40	2318 (14)	196 (15)	252 (12.9)	275 (16)	29 (20)	
>40	393 (2)	24 (2)	45 (2)	73 (4)	3 (2)	
<i>Race/Ethnicity</i>						
White	5873 (36)	292 (22)	588 (30)	1013 (56)	86 (58)	<0.0001
Black	667 (4)	93 (7)	198 (10)	122 (7)	11 (7)	
Hispanic	3844 (23)	349 (26)	610 (31)	402 (23)	35 (24)	
Asian	5447 (33)	539 (40)	498 (25)	135 (7.8)	13 (9)	
Others/Unknown	571 (4)	72 (5)	67 (3)	60 (4)	4 (2.7)	
<i>Marital Status</i>						
Married/Partner	14048 (86)	1074 (80)	1245 (64)	1181 (68)	122 (82)	<0.0001
Divorce/Separated	138 (<1)	15 (1)	55 (3)	91 (5)	2 (1)	
Never married	2178 (13)	253 (19)	652 (33)	456 (26)	24 (16)	
Unknown	38 (<1)	3 (0)	9 (0.5)	4 (0)	1 (0.7)	
<i>Pre-pregnancy BMI</i>						
<18.5	469 (3)	38 (3)	64 (3)	32 (2)	4 (3)	<0.0001
18.5 - <25.0	8054 (54)	680 (54)	886 (48)	685 (40)	69 (47)	
25.0+	6326 (43)	545 (43)	915 (49)	980 (58)	74 (50)	
<i>Parity</i>						
0	7874 (48)	613 (46)	996 (51)	775 (45)	74 (50)	<0.0001
1	5347 (33)	422 (31)	586 (30)	517 (30)	48 (32)	

	No depression n (%)	Untreated depression n (%)	Depression and psychotherapy n (%)	Antidepressant use and depression n (%)	Antidepressant use and no depression n (%)	p-value
Total N	16402 n (%)	1345 n (%)	1961 n (%)	1732 n (%)	149 n (%)	
2+	3015 (18)	297 (22)	355 (18)	423 (24)	25 (17)	
Unknown	166 (1)	13 (1)	24 (1)	17 (1)	2 (1)	
<i>Smoking Status</i>						
No	16150 (99)	1301 (97)	1606 (82)	1402 (81)	123 (83)	<0.0001
Yes	252 (2)	44 (3)	355 (18)	330 (19)	26 (17)	
<i>Alcohol Use</i>						
No	15583 (95)	1281 (95)	1453 (74)	1330 (77)	114 (77)	<0.0001
Yes	819 (5)	64 (5)	508 (26)	402 (23)	35 (24)	
<i>Diabetes (gestational or pre-existing)</i>						
No	13963 (85)	1107 (82)	1699 (87)	1464 (85)	127 (85)	0.0066
Yes	2439 (15)	238 (18)	262 (13)	268 (15)	22 (15)	
<i>Other mental health diseases</i>						
No	16190(99)	1307(97)	1646(84)	1161(67)	132(89)	<0.0001
Yes	212(1)	38(3)	315(16)	571(33)	17(11)	
<i>Other indications for antidepressant medications</i>						
No	13653(83)	1032(77)	1200(61)	532(31)	46(31)	<0.0001
Yes	2749(17)	313(23)	761(39)	1200(69)	103(69)	
<i>Method of depression identification</i>						
DSM-IV	NA	198 (15)	966 (49)	1696 (98)	NA	0.0024
PHQ-9 ≥10	NA	1147 (85)	995 (51)	36 (2)	NA	

Table 2

The Relative Risk of Preeclampsia for Women with Untreated Depression, Depression and Receiving Psychotherapy, Antidepressant Exposure and No Depression, Antidepressant Exposure and Depression, and Timing of Antidepressant Exposure, Among 21,589 pregnant women in Kaiser Permanente Northern California, between 2010 and 2012

	Total n	Preeclampsia n (%)	cRR ^a	95%CI	aRR ^{b,c}	95%CI	cRR	95%CI	aRR ^{b,c}	95%CI
Antidepressant exposure and depression	1732	120 (6.9)	1.62	1.33 - 1.98	1.37	1.06-1.76	1.71	1.24 - 2.37	1.29	0.87 - 1.92
First trimester user only	580	25 (4.3)	0.98	0.65 - 1.48	0.76	0.49-1.19	1.04	0.64 - 1.68	0.74	0.43 - 1.27
Second trimester user ever	1152	95 (8.2)	1.96	1.57 - 2.45	1.7	1.30-2.23	2.07	1.47 - 2.91	1.6	1.06-2.41
Antidepressant exposure and no depression	149	4 (2.7)	0.6	0.22 - 1.63	0.53	0.19 - 1.44	0.64	0.23 - 1.78	0.49	0.17-1.42
First trimester user only	91	0 (0)	-	-	-	-	-	-	-	-
Second trimester user ever	58	4 (6.9)	1.62	0.58 - 4.47	1.34	0.48-3.79	1.71	0.60 - 4.87	1.29	0.44-3.79
Depression and psychotherapy	1961	83 (4.2)	0.96	0.76 - 1.22	0.8	0.61-1.04	1.02	0.72 - 1.44	0.83	0.57 - 1.22
Untreated depression	1345	56 (4.2)	0.95	0.72 - 1.25	0.95	0.71 - 1.27	ref	ref	ref	ref
No depression	16402	719 (4.4)	ref	ref	ref	ref	ref	ref	ref	ref

^a cRR = crude Relative Risk

^b aRR = adjusted Relative Risk

^c adjusted for Pre-pregnancy BMI, maternal age, race/ethnicity, marital status, parity, alcohol use, smoking, diabetes, other indications for antidepressant medications, other mental health diagnoses

Table 3
The Relative Risk of Preeclampsia by the Duration of Antidepressant Medication Exposure During Pregnancy (For All Women Exposed to Antidepressant Medication Regardless of Depression Status) Compared to Women Without Depression

	Total N	Preeclampsia n (%)	cRR ^a	95% CI	aRR ^{b,c}	95% CI
No depression	16402	719 (4.4)	ref	ref	ref	ref
≤60 days	739	42(5.7)	1.31	0.95-1.81	1.05	0.72-1.53
>60 - 120 days	791	56(7.1)	1.66	1.25-2.20	1.38	0.99-1.93
> 120 days	351	26(7.4)	1.75	1.16-2.62	1.47	0.94-2.29

Test of trend: p-value = 0.0114

^a cRR = crude Relative Risk

^b aRR = adjusted Relative Risk

^c adjusted for Pre-pregnancy BMI, maternal age, race/ethnicity, marital status, parity, alcohol use, smoking, diabetes, other indications for antidepressant medications, other mental health diagnoses

Table 4
The Relative Risk of Preeclampsia for Women Taking Antidepressants during Pregnancy, by Class of Antidepressant Medication

	Total N	Preeclampsia n (%)	cRR ^a	95% CI	aRR ^{b,c}	95% CI
No depression	16402	719 (4.4)	ref	ref	ref	ref
TCA exposure						
TCA/TCA plus other antidepressant	154	6 (3.9)	0.88	0.39 - 2.01	0.78	0.33-1.82
TCA only	116	2 (1.7)	0.38	0.10 - 1.55	0.35	0.09-1.47
SSRI exposure						
SSRI only/SSRI plus other antidepressant	1499	106 (7.1)	1.66	1.34 - 2.05	1.4	1.06-1.85
SSRI Only	1262	87 (6.9)	1.62	1.28 - 2.03	1.34	1.00-1.81
SNRI exposure						
SNRI/SNRI plus other antidepressant	113	8 (7.1)	1.66	0.81 - 3.42	1.45	0.66-3.22
SNRI only	72	5 (6.9)	1.63	0.65 - 4.05	1.49	0.57-3.90
NDRI exposure						
NDRI/NDRI plus other antidepressant	236	18 (7.6)	1.8	1.11 - 2.93	1.56	0.90-2.69
NDRI only	118	8 (6.8)	1.59	0.77 - 3.26	1.23	0.57-2.67
SARI exposure						
SARI/SARI plus other antidepressant	144	9 (6.3)	1.45	0.74 - 2.87	1.18	0.56-2.50
SARI only	35	1 (2.9)	0.64	0.09 - 4.69	0.55	0.07-4.09
Other class exposure						
Other Class/Other Class plus other antidepressant	27	1 (3.7)	0.84	0.11 - 6.19	1.03	0.13-7.98
Other class only	11	0	-	-	-	-

^a cRR = crude Relative Risk

^b aRR = adjusted Relative Risk

^c adjusted for Pre-pregnancy BMI, maternal age, race/ethnicity, marital status, parity, alcohol use, smoking, diabetes, other indications for antidepressant medications, other mental health diagnoses